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Abstract
Background: Shoulder pain is one of the most common presentations of musculoskeletal pain with a 1-month
population prevalence of between 7 and 26%. The overall prognosis of shoulder pain is highly variable with 40% of
patients reporting persistent pain 1 year after consulting their primary care clinician. Despite evidence for
prognostic value of a range of patient and disease characteristics, it is not clear whether these factors also predict
(moderate) the effect of specific treatments (such as corticosteroid injection, exercise, or surgery).
Objectives: This study aims to identify predictors of treatment effect (i.e. treatment moderators or effect modifiers)
by investigating the association between a number of pre-defined individual-level factors and the effects of
commonly used treatments on shoulder pain and disability outcomes.
Methods: This will be a meta-analysis using individual participant data (IPD). Eligible trials investigating the
effectiveness of advice and analgesics, corticosteroid injection, physiotherapy-led exercise, psychological
interventions, and/or surgical treatment in patients with shoulder conditions will be identified from systematic
reviews and an updated systematic search for trials, and risk of bias will be assessed. Authors of all eligible trials will
be approached for data sharing. Outcomes measured will be shoulder pain and disability, and our previous work
has identified candidate predictors. The main analysis will be conducted using hierarchical one-stage IPD meta-
analysis models, examining the effect of treatment-predictor interaction on outcome for each of the candidate
predictors and describing relevant subgroup effects where significant interaction effects are detected. Random
effects will be used to account for clustering and heterogeneity. Sensitivity analyses will be based on (i) exclusion of
trials at high risk of bias, (ii) use of restricted cubic splines to model potential non-linear associations for candidate
predictors measured on a continuous scale, and (iii) the use of a two-stage IPD meta-analysis framework.
Discussion: Our study will collate, appraise, and synthesise IPD from multiple studies to examine potential
predictors of treatment effect in order to assess the potential for better and more efficient targeting of specific
treatments for individuals with shoulder pain.
Systematic review registration: PROSPERO CRD42018088298
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Background
Musculoskeletal conditions are globally among the lead-
ing causes of years lived with disability [1]. Shoulder
pain is one of the most common presentations with a 1-
month population prevalence of between 7 and 26% [2].
Annually, about 4% of adults will visit their general prac-
titioner (GP) for shoulder pain [3, 4], resulting in ap-
proximately 1.5 million consultations in England. The
total annual costs of shoulder pain to society have been
estimated at £100 million for the UK [5]. Mean annual
costs per patient have been estimated at £3500 (Sweden)
[6] and £8500 (the USA) [7] per patient, with costs of
surgical interventions and work absence contributing
most to this estimate.
Systematic reviews (e.g. [8–14]) as well as recently
published trials (e.g. [15–18]) consistently show moder-
ate short-term effects of primary care interventions such
as corticosteroid injection and exercise, but a lack of evi-
dence for long-term (> 6months) benefit. The rates of
surgery in the UK increased by more than sevenfold
(750%) for subacromial decompression alone from 5.2/
100,000 in 2001–2002 to 40.2/100,000 in 2009–2010
[19], but there is increasing evidence that some surgical
shoulder interventions are no more effective than non-
surgical treatments or placebo surgery [20–25]. This
demonstrates an increase in the use of healthcare re-
sources, without evidence of improvement in long-term
patient outcomes, and little guidance to support optimal
treatment and referral decisions. The implementation of
more promising or better-targeted treatment for shoul-
der pain is hampered by a lack of high-quality evidence
for the predictive value and clinical utility of diagnostic
and prognostic information.
Clinicians use information from the patient’s clinical
history and physical examination to assess the severity
and possible origin of the problem (rotator cuff tears or
tendinopathy, subacromial bursitis, adhesive capsulitis/
frozen shoulder, acromioclavicular conditions, gleno-
humeral osteoarthritis), although diagnostic accuracy
is limited [26–28]. Qualitative research shows incon-
sistency in the labelling of shoulder conditions and
little impact of diagnostic labels on treatment deci-
sions [29]. Based on their clinical assessment, clini-
cians decide which type of treatment (e.g. advice and
pain relief only; exercise with or without mobilisation;
corticosteroid injection; referral for a specialist (ortho-
paedic) opinion) is most suitable for their patient.
There is little evidence, however, to support such de-
cisions. The uncertainties clinicians experience in the
management of shoulder pain and the different strat-
egies they use to deal with these have been confirmed
in a recent interview study among Dutch GPs [30]
and in surveys conducted in Australia [31] and the
UK [32].
The overall prognosis of shoulder pain is highly vari-
able with 40–50% of patients reporting persistent pain
6–12 months after consulting their primary care clin-
ician [33–36]. In addition to diagnostic information ob-
tained from the clinical assessment, the long-term
prognosis can be influenced by a range of factors,
including age, educational level, symptom duration,
previous episodes, disability scores, and multisite pain
[35–40]. The prognostic value of psychological and so-
cial factors is less clear, but evidence suggests that fear-
avoidance beliefs, pain catastrophizing, depressive symp-
toms, low pain self-efficacy, and aspects of the psycho-
social work environment (high job strain, low
supervisor/co-worker support) are associated with poor
long-term outcome [36, 38, 39, 41–46], particularly in
those with chronic or recurrent shoulder pain [47, 48].
Qualitative research in patients with shoulder pain has
emphasised the anxiety patients experience due to un-
certainty about prognosis and treatment. Patients
highlighted the lack of clear, written information about
the condition and expressed a wish for faster, better-
defined treatment choices [49]. This was confirmed by
results of a recently completed James Lind Alliance Pri-
ority Setting Partnership, with one of the top 10 research
priorities being ‘How can we ensure that patients see the
right clinicians promptly and correctly, and does this
lead to better outcomes?’ [50] Despite evidence for prog-
nostic value of a range of patient and disease character-
istics, it is not clear whether some of these factors may
also predict the effectiveness of specific treatments (such
as corticosteroid injection, exercise, or surgery) in an in-
dividual or subgroups of similar individuals, i.e. modify
or moderate the effect of treatment, and may inform de-
cisions regarding the type of treatment likely to be most
effective for specific (subgroups of ) patients [51]. There
is a clear need for research investigating individual-level
predictors of treatment effect in order to assess the pos-
sibility of better and more efficient targeting of shoulder
pain treatments, potentially improving patient outcomes.
Study objectives
Investigating treatment effect moderation requires data
from randomised controlled trials in order to estimate
candidate treatment-predictor interactions and describe
subgroup effects. A single randomised trial is generally
not powered to detect genuine individual-level predic-
tors. To address this, we will collate and synthesise indi-
vidual participant data (IPD) from multiple trials to
increase the power to identify genuine predictors of
treatment effect. Our aim is to determine moderation of
the effects of four types of treatments that are most
commonly used in the primary care management of
painful shoulder conditions and where evidence regard-
ing predictors of treatment effect would inform
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decisions regarding their optimal use: (a) corticoster-
oid injection, (b) physiotherapy-led exercise, (c) psy-
chological treatments, and (d) surgical interventions
on shoulder pain and disability outcomes by a limited
number of a priori defined individual-level candidate
predictors (patient characteristics). The IPD meta-
analysis will be conducted in three steps with the fol-
lowing objectives:
1. To estimate the overall effects of each of these four
treatments separately, when compared to a control
intervention (no treatment, advice and analgesics
only, or sham)
2. To estimate the relative effects when these
interventions are directly compared against each
other in pragmatic randomised trials
3. Within each of these comparisons separately, to
estimate treatment-predictor interactions for a
number of a priori defined patient or disease char-
acteristics and describe relevant subgroup effects
when interactions are detected
The results of the IPD meta-analysis will be used to
define profiles of patients with shoulder pain likely to
respond well to each of the treatments listed above. As
part of a larger programme of research, the IPD meta-
analysis will form the basis of the design of a treatment
decision tool for patients consulting with shoulder pain
in primary care, to be used as part of a stratified care
intervention and tested against usual care for shoulder
pain in a large pragmatic randomised controlled trial.
Methods
An a priori protocol was established for this IPD meta-
analysis and registered with the international prospective
register of systematic reviews: PROSPERO (www.crd.
york.ac.uk/prospero/), number CRD42018088298.
Eligibility criteria (see also Table 1)
Design and setting
IPD will be included from randomised clinical trials con-
ducted in the community, primary healthcare, or sec-
ondary healthcare settings. No language restrictions will
be used.
Study population
The IPD meta-analysis will include trials conducted in
adult patients with general or non-specified shoulder
Table 1 Eligibility criteria for including trials in the IPD meta-analysis
Include Exclude
Design Randomised clinical trials, including individual and cluster-randomised trials, no
language restrictions
Any other non-randomised design
Setting Any healthcare setting Preventative intervention studies (e.g. in workplace
settings)
Population ▪ Adults (18 years and older)
▪ General or non-specified shoulder pain or diagnosed with (i) subacromial con-
dition (rotator cuff tendinopathy, rotator cuff tear, subacromial bursitis), (ii) frozen
shoulder/adhesive capsulitis, (iii) glenohumeral osteoarthritis, (iv) shoulder
instability.
▪ Acute trauma (fractures, traumatic dislocations)
▪ Inflammatory arthritis (rheumatoid arthritis,
polymyalgia rheumatica)
▪ Shoulder pain resulting from cervical
radiculopathy
▪ Stroke-related shoulder pain
Interventions ▪ Corticosteroid injection
▪ Physiotherapy-led exercise (with or without manual therapy)
▪ Interventions addressing psychological factors (e.g. cognitive behavioural
approaches, multimodal interventions)
▪ Surgical interventions
Other, less common treatment options, or
treatments with very limited evidence of
effectiveness
Control ▪ Advice and pain relief only
▪ Sham/placebo intervention
▪ Direct comparisons between the interventions listed above
▪ Comparisons with other interventions
▪ Comparisons of different dosages, types, or modes
of delivery of the same intervention
Outcome
measure
▪ Shoulder pain intensity (VAS, 0–10 NRS, validated shoulder-pain specific
questionnaire)
▪ Shoulder function (NRS, VAS, validated shoulder disability questionnaire).
No baseline and follow-up data for either one of
these outcomes
Candidate
predictors
At least one of the following potential predictors in addition to baseline levels
of the outcome measure (pain or disability): shoulder pain duration, sleep
disturbance due to shoulder pain, presence of weakness, cause of shoulder pain
(injury, or overuse due to work/hobbies), co-existing neck pain, psychosocial
complexity (fear-avoidance, catastrophizing, anxiety, depression, other), positive
expectations or preferences regarding treatment, presence of comorbidities.
Length of
follow-up
Follow-up assessment at least 4 weeks after randomisation Trials including only very short-term follow-up (e.g.
after a single intervention session)
Sample size Minimum sample size at randomisation, 30 per intervention arm
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pain or diagnosed with subacromial conditions including
rotator cuff tears, rotator cuff tendinopathy, subacromial
impingement, or subacromial bursitis; (ii) frozen shoul-
der or adhesive capsulitis; (iii) glenohumeral osteoarth-
ritis; and (iv) shoulder instability. The IPD meta-analysis
will not include trials focusing on acute trauma (frac-
tures, traumatic dislocations), inflammatory arthritis,
shoulder pain resulting from cervical radiculopathy, or
stroke-related shoulder pain.
Interventions
The IPD meta-analysis will focus on interventions that
are commonly used in the primary care management of
shoulder pain in the UK. Trials will be included that in-
vestigate the effectiveness of the following:
 Corticosteroid injection versus injection of an
anaesthetic only or compared with control (advice
and analgesics or no additional treatment)
 Physiotherapy-led exercise therapy (with/without
manual therapy) compared with control (advice and
analgesics or no additional treatment)
 Corticosteroid injection compared with
physiotherapy-led exercise therapy (with/without
manual therapy)
Primary care clinicians may also consider referral of
patients with shoulder pain to secondary care services,
offering more extensive treatments for shoulder pain.
We will therefore also include trials investigating the ef-
fectiveness of the following:
 Interventions incorporating assessment and
management of psychological risk factors, such as
cognitive-behavioural approaches, or multimodal
treatment programmes compared with exercise, in-
jection, and/or control (advice and analgesics or no
additional treatment)
 Surgical treatment compared with non-surgical
treatment (exercise, injection) and/or control (advice
and analgesics or sham surgery)
Outcome measures
We will include trials that have used (i) a measure of
shoulder pain (e.g. visual analog scale (VAS), 0–10 NRS,
validated shoulder-pain specific questionnaires) and/or
(ii) a measure of shoulder pain related disability (NRS,
VAS, validated shoulder disability questionnaires).
Length of follow-up
Trials will be included that have a follow-up assessment
at least 4 weeks after randomisation. Outcomes will be
analysed for up to 24months after randomisation.
Sample size
In order to reduce the risk of small-study bias, we will
only include trials with a sample size of at least 30 par-
ticipants per treatment arm at the time of randomisa-
tion. This cut-point is arbitrary, but will ensure we
obtain data for the largest trials. Furthermore, excluding
the smallest trials will allow a more efficient approach to
collecting data for this IPD meta-analysis, which is
otherwise known to be very time-consuming [52]. Smal-
lest trials are also more prone to baseline imbalance (by
chance), and thus their exclusion will reduce the risk of
identifying spurious treatment effects and treatment-
predictor interactions.
Candidate predictors
Developmental work has been conducted which has gen-
erated a shortlist of candidate predictors to be analysed
in this IPD meta-analysis. A systematic review of rando-
mised clinical trials identified 21 trials that investigated
or suggested candidate predictors of the effects of treat-
ment with corticosteroid injection, strengthening exer-
cise and/or mobilisation, or advice and pain relief [53].
Only 7 trials included a moderation analysis or subgroup
analysis, whereas 14 trials made untested suggestions of
effect modification. The results of the systematic review
informed a series of workshops with clinicians, who pro-
posed profiles of patients most likely to respond to these
treatments, and prioritised a list of 12 potential predic-
tors. These 12 candidate predictors formed the basis of
an international choice-based conjoint analysis survey
[53], and most of these will be tested in the proposed
IPD meta-analysis: baseline pain severity, baseline dis-
ability, sleep disturbance due to shoulder pain, presence
of instability or weakness, cause of shoulder pain (injury
or overuse due to work/hobbies), co-existing neck pain,
psychosocial complexity (fear-avoidance, catastrophizing,
anxiety, depression), positive expectations or preferences
regarding treatment, and presence of comorbidities.
Additionally, the author team suggested shoulder pain
duration as an important candidate predictor of treat-
ment effect.
Patient and public involvement
The perspectives of patients and clinicians involved in
the management of shoulder pain be included in the de-
sign and reporting of the IPD meta-analysis, by involving
an advisory group of people with experience of living
with shoulder pain, and a clinical advisory group includ-
ing physiotherapists, rheumatologists, GPs, and ortho-
paedic surgeons. Patient representatives will be invited
from Keele University Research User Group. The advis-
ory groups will be consulted regarding (i) candidate pre-
dictors and outcomes, (ii) interpretation and importance
of findings to patients and clinicians, and (iii) how best
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to present the findings to the general public, patients,
and clinicians.
Searching and selection
Potentially eligible trials were identified through existing
relevant systematic reviews and an updated search of in-
dividual trials published after the search dates of these
reviews (up until May 2018). Updated searches of elec-
tronic databases (restricted to randomised controlled tri-
als) included MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trials (CENTRAL), PEDro, WHO
ICTRP, and ClinicalTrials.gov. Table 2 presents the
searches for MEDLINE (through Ovid) as an example;
search terms were adapted for other databases. Citations
will be imported into Covidence for screening and
selection.
Two reviewers will screen titles and abstracts of trials
identified from these searches against the eligibility cri-
teria described above, excluding trials that clearly do not
meet the eligibility criteria. Subsequently, full texts of
trial reports will be retrieved and assessed for eligibility,
again by two reviewers independently. Disagreements
will be resolved through discussion or by third reviewer
adjudication. Trial authors will be contacted if there are
queries regarding eligibility.
Extraction of aggregate data
For each included trial, details on study design (random-
isation and allocation procedure), study setting, sample
size, baseline characteristics of the study sample (age,
gender, diagnosis, duration and history of shoulder pain),
details of interventions (type of treatment, duration, fre-
quency, dose, co-interventions), comparator (advice, an-
algesics, other), candidate predictors, and outcome
assessment (type of outcome measure, timing of follow-
up, numbers lost to follow-up) will be extracted into ta-
bles. Two reviewers will independently extract outcome
data on self-reported pain and disability at time points
nearest to 6 weeks (short-term), 3–6 months (medium-
term), and ≥ 12 months (long-term).
Risk of bias assessment
All trials identified from our searches will be assessed
using the Cochrane Risk of Bias tool, regardless of
whether they supply their IPD or not. Two researchers
will independently grade risk of bias (unclear, high, or
low risk of bias) based on sequence generation, alloca-
tion concealment, blinding of outcome assessor, incom-
plete outcome data, and selective outcome reporting.
Although our aim is to obtain IPD from all studies, we
recognise some teams may decline or no longer have ac-
cess to data [54]. In this situation, we will also compare
the risk of bias for those studies that do and do not pro-
vide their IPD. Studies providing their IPD will have a
more thorough examination of their risk of bias, as as-
pects of design and conduct can be checked with the
trial team, and the IPD allows an examination of some
aspects to a greater detail (e.g. baseline balance and
missing information) than possible with the study publi-
cation alone [55].
Data transfer and quality assurance of individual
participant data
Principal investigators (PIs) or corresponding authors of
identified trials will be contacted to inform them about
the study and ask if they would be willing to share IPD.
If there is no response, the institutes (e.g. head of de-
partment or research group) in which the trials have
been performed will be contacted.
Those who express an interest in collaboration will be
invited to read the protocol and requirements for shar-
ing IPD will be discussed. The data custodian/represen-
tative of the institute who owns the data will then be
invited to sign a data sharing agreement, which specifies
the data requested, obligations, ownership of data,
terms, authorship, and publications.
IPD requested from each trial will include the
following:
 Baseline characteristics of participants
(sociodemographic variables, characteristics of the
shoulder condition, data regarding all candidate
moderating variables)
 Randomisation code indicating random treatment
allocation, any variables indicating non-adherence to
protocol (protocol deviations), and duration and
number of treatment sessions if these vary between
individual participants
 Baseline and follow-up data regarding pain and dis-
ability outcomes at each time-point, where relevant
including final scores for multi-item scales, and sub-
scale scores for multidimensional scales (e.g. pain
and function for SPADI). If available, EQ-5D will be
requested as it contains items for pain and disability
and may be used if trials have not included specific
scales for pain or disability.
Trial authors will be asked to share relevant data re-
garding candidate predictors and outcomes regardless of
whether such data has previously appeared in trial publi-
cations. The IPD received will not be used for any other
research apart from that described in the data sharing
agreement. All collaborators (one representative per
trial) will be invited to be co-authors on manuscripts de-
scribing the principal analyses outlined in this protocol,
subject to them meeting the International Committee of
Medical Journal Editors criteria for authorship.
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Table 2 Searches to identify systematic reviews and potentially eligible trials (MEDLINE via Ovid)
Systematic reviews Randomised clinical trials
1. exp Shoulder Joint/ 1. exp PAIN/
2. shoulder.ti,ab. 2. exp Shoulder Joint/
3. “rotator cuff”.ti,ab. 3. 1 and 2
4. glenohumeral.ti,ab. 4. Shoulder Pain/
5. subacromia$.ti,ab. 5. Shoulder Impingement Syndrome/
6. or/1-6 6. exp Bursitis/
7. Pain/ or pain.ti,ab. 7. rotator cuff/
8. 6 and 7 8. ((shoulder or subacromial or glenohumeral or rotator cuff)
adj3 (instability or bursitis or frozen or impingement or tendinitis
or tendonitis or pain$ or osteoarthr$ or periarthriti$)).ti,ab.
9. exp Shoulder Pain/ 9. “adhesive capsulitis”.ti,ab.
10. “adhesive capsulitis”.ti,ab. 10. or/3-9
11. Shoulder Impingement Syndrome/ 11. exp Adrenal Cortex Hormones/
12. or/8-11 12. (steroid or corticosteroid).ti,ab.
13. Meta-Analysis as Topic/ 13. 11 or 12
14. meta analy$.tw. 14. inject$.ti,ab.
15. metaanaly$.tw. 15. 13 and 14
16. Meta-Analysis/ 16. exp Exercise/ or exp Exercise Therapy/
17. (systematic adj (review$1 or overview$1)).tw. 17. exercise$.ti,ab.
18. exp Review Literature as Topic/ 18. 16 or 17
19. OR/13-18 19. exp Musculoskeletal Manipulations/
20. cochrane.ab. 20. (“manual therapy” or manipulation$ or mobilisation$).ti,ab.
21. embase.ab. 21. (chiropract$ or osteopath$).ti,ab.
22. (psychlit or psyclit).ab. 22. 19 or 20 or 21
23. (psychinfo or psycinfo).ab. 23. exp adaptation, psychological/ or exp behavior/ or exp psychology, social/
24. (cinahl or cinhal).ab. 24. (psychosocial or psycholog$).ti,ab.
25. science citation index.ab. 25. behavio$.ti,ab.
26. bids.ab. 26. 23 or 24 or 25
27. cancerlit.ab. 27. (surgery or surgical or operat$).ti,ab.
28. “web of science”.ab. 28. exp orthopedic procedures/ or orthopedics/
29. or/20-28 29. 27 or 28
30. reference list$.ab. 30. (physio$ or physical therap$).ti,ab.
31. bibliograph$.ab. 31. exp Physical Therapy Modalities/
32. hand-search$.ab. 32. 30 or 31
33. relevant journals.ab. 33. 15 or 18 or 22 or 26 or 29 or 32
34. manual search$.ab. 34. 10 and 33
35. or 30-34 35. random$.ti,ab.
36. selection criteria.ab. 36. factorial$.ti,ab.
37. data extraction.ab. 37. crossover$.ti,ab.
38. 36 or 37 38. cross over$.ti,ab.
39. Review/ 39. placebo$.ti,ab.
40. 66 and 67 40. (doub$ adj blind$).ti,ab.
41. Comment/ 41. (sing$ adj blind$).ti,ab.
42. Letter/ 42. assign$.ti,ab.
43. Editorial/ 43. allocat$.ti,ab.
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Collaborators will be invited to send their anonymised
dataset as an encrypted file to the host institution, where
this will be stored on a secure server. Prior to data trans-
fer, there will be a process to verify that the person receiv-
ing the data is the accurate and intended recipient for the
data. Any additional processes or requirements for data
transfer stipulated by the collaborating institutions will be
adhered to. Datasets will be accepted in any form, pro-
vided that all data are anonymised and variables and cat-
egories are adequately labelled in English. However,
ideally, the format will be a two-dimensional spreadsheet
with one participant per row and variables listed in col-
umns and different time points on separate spreadsheets.
Datasets will be examined for missing and unusual
values, with any issues resolved through communication
with the original authors. We will attempt to reproduce the
results included in each initial trial publication, including
baseline characteristics and self-reported pain and disability
at a time point nearest to 6 weeks, 3–6months, and 12
months. Discrepancies or missing information will be dis-
cussed and clarified with original trial authors, where pos-
sible requesting analysis scripts. Following satisfactory data
checking, each dataset will be converted to a common for-
mat and variables will be renamed in a consistent manner.
The original scales of outcomes and covariate measure-
ments that are reported will be utilised, where possible. To
ensure compatibility across studies, when required, at-
tempts will be made to convert variables to the same scale
for all studies, by seeking to standardise the scale for out-
comes and covariate measurements, for example, convert-
ing continuous outcomes to a standardised (e.g. N (0,1))
scale, by subtracting individual outcome values by the mean
in the same study and then dividing by the standard devi-
ation of values across individuals in the same study. Once
each study data is cleaned and standardised, individual trial
datasets will then be combined to form a new master data-
set with a variable added to indicate the original trial.
Approaches to dealing with missing participant-level data
in trials
Participant-level missing data on candidate predictors
and individual outcomes will be described. Under a
‘missing-at-random’ assumption, and where repeated
outcome measures are available over time, individuals
with partially missing outcome data (e.g. at some time-
points) will be included in analyses (without imputation)
using a longitudinal data (multi-level) modelling frame-
work. Otherwise, they will be excluded, as this does not
bias results for trials assuming the outcomes are missing
at random [56]. If there is a considerable amount of
missing baseline data for candidate predictors or covari-
ates of interest (e.g. age, gender), this will be handled
using multiple imputation, for those variables where a
‘missing-at-random’ assumption is deemed appropriate.
Subsequently, for each meta-analysis, Rubin’s rule will
be used to combine meta-analysis results across the im-
puted datasets [57].
Analysis
General approach to the IPD meta-analysis
The IPD meta-analysis will be conducted in two steps:
(1) estimating overall treatment effects on shoulder pain
and disability outcomes for each of the treatment com-
parisons listed in objectives 1 and , and (2) estimating
treatment-predictor interactions within each of the com-
parisons and separately for each of the candidate predic-
tors (objective 3). We expect few trials will include data
on all candidate predictors, and therefore, it is not our
intention to develop a full prediction model that would
consider all candidate predictors in a single model. Each
of the candidate predictors will be separately tested for
effect modification, using all trial datasets that have pro-
vided sufficient data on the treatment comparison, can-
didate predictor, and outcome measure.
For both steps, the IPD meta-analysis can be con-
ducted using either a one-stage or two-stage approach
[58]. Both approaches will be used in this IPD meta-
analysis, with the two-stage approach being conducted
as a sensitivity analysis. A two-stage approach is often
preferred, as this approach automatically ensures that
clustering of participants within trials is accounted for
and aggregation bias can be avoided, which is more
likely in a one-stage approach [59, 60]. This approach
also allows the use of the Hartung-Knapp correction to
Table 2 Searches to identify systematic reviews and potentially eligible trials (MEDLINE via Ovid) (Continued)
Systematic reviews Randomised clinical trials
44. animal/ 44. volunteer$.ti,ab.
45. human/ 45. double-blind procedure/
46. 44 not (44 and 45) 46. crossover-procedure/
47. 41 or 42 or 43 or 46 47. randomized controlled trial/
48. 19 or 29 or 35 or 40 48. single-blind procedure/
49. 48 not 47 49. or/35-48
50. 12 and 49 50. 34 and 49
Windt et al. Diagnostic and Prognostic Research            (2019) 3:15 Page 7 of 11
inflate confidence intervals, accounting for the uncer-
tainty of the estimated between-study variance [61].
However, the one-stage approach is likely to be more
practical for modelling of non-linear associations of can-
didate predictors with outcome. Therefore, the analysis
will be conducted using the one-stage approach (hier-
archical model which will include both study-level and
patient-level covariates in the same model), if possible
using the Kenward-Roger method to inflate confidence
intervals to account more fully for the uncertainty of
variance estimates. Clustering will be accounted for by
using a separate intercept per study and with separate
residual variance and adjustment terms per study. Ran-
dom treatment effects and treatment-predictor inter-
action terms will be included to allow for potential
heterogeneity. Candidate predictors will be centred by
their mean to avoid ecological bias [62]. A two-stage
analysis will be performed as a sensitivity analysis to
check whether conclusions are consistent.
Outcome measures
All analyses will be conducted for (i) severity of shoulder
pain, measured using either a 0–10 numerical rating
scale, 0–100 VAS, or pain scale (e.g. SPADI pain sub-
scale), and (ii) level of shoulder function, measured using
a validated shoulder disability questionnaire, with trials
contributing to the analysis if they have provided suffi-
cient data on any one of these measures.
IPD meta-analysis models
All analyses will be carried out using Stata 15 [63] or
SAS 9.3 [64]. All analyses will be performed based on an
intention-to-treat principle. All models will allow for
random effects and will be estimated using restricted
maximum likelihood (REML).
For both outcomes (shoulder pain and disability
scores), the IPD meta-analysis will utilise a linear regres-
sion framework, where the final pain/disability score will
be regressed against the baseline score, the treatment ef-
fect, the candidate predictor, and the interaction term. If
studies use different pain or disability scales, these will
be converted to a common scale if possible or otherwise
estimates will be expressed as standardised mean differ-
ence. If standardised scales are required, the standar-
dised final score will be regressed and the standardised
baseline score adjusted for. For trials that contained
multiple centres or a cluster-design, the hierarchical
model will handle the clustering appropriately. Continu-
ous candidate predictors will be entered as a linear term
primarily, but sensitivity analysis will examine if non-
linear trends are more plausible, using restricted cubic
splines [65].
Adjustment for age and gender, as well as baseline
pain/disability score, will be made in all analyses [66]. If
there are repeated follow-up scores, the model will be
adapted to include a repeated measures model where all
follow-up times are jointly analysed, and the correlation
among repeated measures from the same participants
accounted for [67]. This approach can naturally handle
missing follow-up scores for some patients, under a
missing at random assumption. Treatment-predictor in-
teractions may vary between time points, which will be
an important criterion when interpreting statistically sig-
nificant interaction terms (p < 0.10). Consistent evidence
across multiple time points will add credence to it being
a genuine (causal) predictor of treatment response [68].
Any model convergence problems will be reported
clearly.
Data presentation
All summary and study-specific results will be presented
in tables and via forest plots, with heterogeneity dissemi-
nated by I-squared, estimates of between-study variance
and approximate 95% prediction intervals [69]. The en-
tire process with be reported according to the PRISMA-
IPD guidelines [70]. Overall treatment effects and treat-
ment effects for each relevant subgroup (where signifi-
cant treatment-predictor interactions will be identified)
will be produced.
Small-study effects
Small-study effects refer to systematic differences in the
effects from bigger and smaller studies and may occur
due to many reasons, such as publication bias, hetero-
geneity, and availability bias (i.e. non-participation of tri-
als toward the IPD meta-analysis). As mentioned, we
aim to reduce the risk of small study bias by only includ-
ing trials with a sample size of at least 30 participants
per arm at the time of randomisation. However, in meta-
analyses of 10 trials or more, small-study effects (which
may highlight the potential for publication bias and
availability bias) will be examined using contour-
enhanced funnel plots and tests for asymmetry such as
Egger’s test and Peter’s test [71]. In the presence of fewer
than 10 trials, there is low power to detect small-study
effects [72].
Sensitivity analyses
Sensitivity analyses will be carried out to assess the influ-
ence of important methodological factors and assess the
robustness of the results of the main analysis. Sensitivity
analyses will be based on (i) exclusion of trials studies at
high risk of bias, (ii) use of restricted cubic splines to
model potential non-linear associations for candidate
predictors measured on a continuous scale, and (iii) the
use of a two-stage IPD meta-analysis framework. For the
latter, in the first stage, each trial providing IPD will be
analysed separately to provide interaction estimates
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between each candidate predictor and treatment effect.
Then, in the second stage, the interaction estimates will
be synthesised using a random-effects meta-analysis, to
produce a summary interaction estimate for each candi-
date predictor. REML will be used to estimate the
random-effects meta-analysis models, with 95% confi-
dence intervals for summary effects derived using the
Hartung-Knapp approach to account for uncertainty in
the estimated variance terms [73, 74]. Overall treatment
effects and treatment effects for each subgroup will be
produced (where significant treatment-predictor interac-
tions are identified). For non-linear interactions, the sec-
ond stage will use a multivariate meta-analysis model [75].
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